Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

NovaBay Pharmaceuticals Inc (NYSE MKT LLC:NBY)

4.05
Delayed Data
As of Jul 24
 +0.15 / +3.85%
Today’s Change
2.12
Today|||52-Week Range
5.29
+22.73%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$59.7M

Company Description

NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in developing products for the eye care. The company's products include Avenova, which is designed to remove foreign materials including microorganisms and debris on and around the lid and eyelid margins that may be due to Blepharitis, Meibomian Gland Dysfunction and dry eye; NeutroPhase, is a skin and wound cleanser consisting of neutrox; and cellerx, it cleans, calms and soothes skins. NovaBay Pharmaceuticals was founded by Ramin Najafi on January 19, 2000 and is headquartered in Emeryville, CA.

Contact Information

NovaBay Pharmaceuticals, Inc.
2000 Powell Street
Emeryville California 94608
P:(510) 899-8800
Investor Relations:
(510) 899-8809

Employees

Shareholders

Individual stakeholders66.92%
Other institutional0.73%
Mutual fund holders0.32%

Top Executives

Mark M. SieczkarekChairman, President & Chief Executive Officer
Jack J. McGovernChief Financial Officer
Justin M. HallSenior Vice President & General Counsel
Tom PaulsonSecretary, Treasurer & Head-Investor Relations
Glenn MoroVice President-Marketing & Sales